Clinical Trial Update: Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding [Phase 2]

View source ↗

Summary

Phase 2 clinical trial results indicate that thalidomide reduced gastrointestinal bleeding related to arteriovenous malformations in patients with hereditary he…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arteriovenous Malformation
• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: Northport Veterans Affairs Medical Center | Conditions: Arteriovenous Malformation, Hereditary Hemorrhagic Telangiectasia | Phase 2 | Status: COMPLETED